EPIRUBICIN AND IFOSFAMIDE IN ADVANCED SOFT-TISSUE SARCOMAS

被引:24
作者
FRUSTACI, S
FOLADORE, S
BUONADONNA, A
DEPAOLI, A
CRIVELLARI, D
CARBONE, A
SORIO, R
MORASSUT, S
MONFARDINI, S
机构
[1] CTR RIFERIMENTO ONCOL,DEPT RADIAT THERAPY,I-33081 AVIANO,ITALY
[2] CTR RIFERIMENTO ONCOL,DIV PATHOL,I-33081 AVIANO,ITALY
[3] CTR RIFERIMENTO ONCOL,RADIOL SERV,I-33081 AVIANO,ITALY
关键词
CHEMOTHERAPY; EPIRUBICIN; IFOSFAMIDE; METASTATIC SOFT TISSUE SARCOMAS;
D O I
10.1093/oxfordjournals.annonc.a058622
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To evaluate the feasibility, toxicity and efficacy of the combination of (IFO) ifosfamide and epirubicin (EPI) given at conventional doses for monochemotherapy, we started a phase II study in advanced/metastatic soft tissue sarcoma patients. Patients and methods: Treatment consisted of: epirubicin 75 mg/m2 i.v. day 1; IFO 1.8 g/m2 days 1 to 5; MESNA 20% of the IFO dose at 4-hour intervals three times a day during IFO administration. Cycles were given every 3-4 weeks for at least three cycles. Results: The overall response rate for non-visceral sarcomas (51 pts) ws 31% (95% confidence limits +/- 13%). Among the 13 visceral sarcomas no response was seen for the leiomyosarcomas of the gastrointestinal tract, whereas one complete and one partial remission were observed for the uterine sarcomas. The duration of response was 10 months (range 5-34+) for complete responses and 9 (range 4-42+) for partial responses. The median survival for responders is 18 months (range 2-60+) and for non-responders 10 months (range 1-33) (p < 0.004). Conclusions: This combination proved to be feasible and tolerable. The overall response rate does not appear to be superior to those with other standard treatments, but it should be pointed out that our patient population was totally unselected.
引用
收藏
页码:669 / 672
页数:4
相关论文
共 50 条
  • [41] Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies
    S Leyvraz
    R Herrmann
    L Guillou
    H P Honegger
    A Christinat
    M F Fey
    C Sessa
    M Wernli
    T Cerny
    D Dietrich
    B Pestalozzi
    British Journal of Cancer, 2006, 95 : 1342 - 1347
  • [42] Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas
    Jeronimo Rafael Rodriguez-Cid
    Juan Jose Juarez-Vignon Whaley
    Gisela Sánchez-Domínguez
    Jordi Guzmán-Casta
    Sonia Carrasco-CaraChards
    Jorge Guzmán-Huesca
    Rodrigo Riera-Sala
    Carla Paola Sánchez-Ríos
    Mayte Cruz-Zermeño
    Alec Seidman-Sorsby
    Ivan de Jesús Rodríguez-Zea
    Jorge Arturo Alatorre-Alexander
    Luis Manuel Martínez-Barrera
    Patricio Javier Santillán-Doherty
    Aminadab Godina-Flores
    Victoria Imaz-Olguin
    Ricardo Sosa-Sánchez
    Dan Green-Renner
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 5479 - 5491
  • [43] Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas
    Rodriguez-Cid, Jeronimo Rafael
    Juarez-Vignon Whaley, Juan Jose
    Sanchez-Dominguez, Gisela
    Guzman-Casta, Jordi
    Carrasco-CaraChards, Sonia
    Guzman-Huesca, Jorge
    Riera-Sala, Rodrigo
    Sanchez-Rios, Carla Paola
    Cruz-Zermeno, Mayte
    Seidman-Sorsby, Alec
    Rodriguez-Zea, Ivan de Jesus
    Alatorre-Alexander, Jorge Arturo
    Martinez-Barrera, Luis Manuel
    Santillan-Doherty, Patricio Javier
    Godina-Flores, Aminadab
    Imaz-Olguin, Victoria
    Sosa-Sanchez, Ricardo
    Green-Renner, Dan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (09) : 5479 - 5491
  • [44] Effect of high-dose ifosfamide in advanced soft tissue sarcomas.: A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
    Nielsen, OS
    Judson, I
    van Hoesel, Q
    le Cesne, A
    Keizer, HJ
    Blay, JY
    van Oosterom, A
    Radford, JA
    Svancárová, L
    Krzemienlecki, K
    Hermans, C
    van Glabbeke, M
    Oosterhuis, JW
    Verweij, J
    EUROPEAN JOURNAL OF CANCER, 2000, 36 (01) : 61 - 67
  • [45] Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous infusion etoposide
    Saeter, G
    Talle, K
    Solheim, OP
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 36 (02) : 172 - 175
  • [46] Trabectedin for advanced soft tissue sarcomas: optimizing use
    Reid, Alison
    Martin-Liberal, Juan
    Benson, Charlotte
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2014, 10 : 1003 - 1011
  • [47] Safety evaluation of trabectedin in treatment of soft-tissue sarcomas
    Martin-Liberal, Juan
    Judson, Ian
    EXPERT OPINION ON DRUG SAFETY, 2013, 12 (06) : 905 - 911
  • [48] Surgical Management of Retroperitoneal Soft-Tissue Sarcomas - An Overview
    Garlipp, B.
    Schulz, H. -U.
    Zeile, M.
    Lippert, H.
    Meyer, F.
    ZENTRALBLATT FUR CHIRURGIE, 2010, 135 (06): : 564 - 574
  • [49] Controversies and consensus of neoadjuvant chemotherapy in soft-tissue sarcomas
    Loong, Herbert H.
    Wong, Kwan-Hung
    Tse, Teresa
    ESMO OPEN, 2018, 3
  • [50] Gemcitabine in advanced adult soft-tissue sarcomas.: A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
    Svancárová, L
    Blay, JY
    Judson, IR
    van Hoesel, QGCM
    van Oosterom, AT
    le Cesne, A
    Keizer, HJ
    Hermans, C
    van Glabbeke, M
    Verweij, J
    Hogendoorn, PCW
    Nielsen, OS
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (04) : 556 - 559